Sandoz has agreed to postpone its generic version of a cataract surgery drug made by biopharmaceutical company Omeros, ending a patent infringement lawsuit between the two in Delaware.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
21 May 2026 European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration.
20 May 2026 The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.
19 May 2026 In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".
